Free Trial

Equillium (EQ) Competitors

Equillium logo
$0.32 0.00 (-0.93%)
As of 09:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EQ vs. ALGS, ABVC, ATNM, MURA, SCLX, GRCE, STTK, ITRM, ANVS, and PLUR

Should you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Aligos Therapeutics (ALGS), ABVC BioPharma (ABVC), Actinium Pharmaceuticals (ATNM), Mural Oncology (MURA), Scilex (SCLX), Grace Therapeutics (GRCE), Shattuck Labs (STTK), Iterum Therapeutics (ITRM), Annovis Bio (ANVS), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry.

Equillium vs. Its Competitors

Aligos Therapeutics (NASDAQ:ALGS) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

In the previous week, Aligos Therapeutics' average media sentiment score of 0.00 equaled Equillium'saverage media sentiment score.

Company Overall Sentiment
Aligos Therapeutics Neutral
Equillium Neutral

Equillium has a net margin of -19.62% compared to Aligos Therapeutics' net margin of -1,628.75%. Aligos Therapeutics' return on equity of 14.67% beat Equillium's return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-1,628.75% 14.67% 7.19%
Equillium -19.62%-74.34%-46.75%

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 4.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 30.3% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aligos Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the S&P 500. Comparatively, Equillium has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Aligos Therapeutics currently has a consensus price target of $70.00, suggesting a potential upside of 826.54%. Equillium has a consensus price target of $3.00, suggesting a potential upside of 843.40%. Given Equillium's higher possible upside, analysts plainly believe Equillium is more favorable than Aligos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Equillium
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Equillium has higher revenue and earnings than Aligos Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$3.94M11.72-$131.21M-$17.51-0.43
Equillium$41.10M0.28-$8.07M-$0.39-0.82

Summary

Aligos Therapeutics beats Equillium on 7 of the 13 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EQ vs. The Competition

MetricEquilliumMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.68M$2.89B$5.53B$9.02B
Dividend YieldN/A2.44%5.22%3.99%
P/E Ratio-0.8421.7127.8120.25
Price / Sales0.28283.26429.10119.26
Price / CashN/A41.7026.2128.59
Price / Book0.597.538.025.65
Net Income-$8.07M-$55.14M$3.18B$249.15M
7 Day Performance0.89%4.22%2.88%2.91%
1 Month Performance-16.32%0.91%1.66%4.11%
1 Year Performance-53.23%5.40%34.25%20.98%

Equillium Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EQ
Equillium
1.8074 of 5 stars
$0.32
-0.9%
$3.00
+843.4%
-51.9%$11.68M$41.10M-0.8440Gap Up
ALGS
Aligos Therapeutics
3.1162 of 5 stars
$7.21
flat
$70.00
+870.9%
-21.3%$44.08M$3.94M-0.4190
ABVC
ABVC BioPharma
0.6823 of 5 stars
$2.22
-14.3%
N/A+309.5%$43.98M$508.38K-17.0830Positive News
High Trading Volume
ATNM
Actinium Pharmaceuticals
2.807 of 5 stars
$1.40
-1.4%
$4.00
+185.7%
N/A$43.67M$81K-1.0130
MURA
Mural Oncology
3.0635 of 5 stars
$2.47
-0.4%
$12.00
+385.8%
-12.8%$42.83MN/A-0.32119
SCLX
Scilex
1.5577 of 5 stars
$5.89
-2.6%
$455.00
+7,625.0%
-90.9%$42.06M$56.59M-0.2080
GRCE
Grace Therapeutics
1.7519 of 5 stars
$2.97
flat
$12.00
+304.0%
N/A$41.07MN/A-3.34N/A
STTK
Shattuck Labs
2.8465 of 5 stars
$0.79
-7.3%
$7.50
+847.2%
-77.3%$40.89M$5.72M-0.57100Positive News
ITRM
Iterum Therapeutics
1.8841 of 5 stars
$1.00
-1.5%
$9.00
+804.5%
-17.3%$40.40MN/A-1.0110
ANVS
Annovis Bio
1.4995 of 5 stars
$2.18
+6.3%
$30.25
+1,287.6%
-78.5%$39.95MN/A-1.013
PLUR
Pluri
3.55 of 5 stars
$4.95
-2.8%
$12.00
+142.4%
-4.5%$39.87M$330K-0.90150Positive News

Related Companies and Tools


This page (NASDAQ:EQ) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners